Neuland Laboratories Ltd.

NSE: NEULANDLAB | BSE: 524558 | ISIN: INE794A01010 | Industry: Pharmaceuticals
| Expensive Performer
11070.6000 112.45 (1.03%)
NSE Mar 13, 2025 15:31 PM
Volume: 52,775
 

11070.60
1.03%
BP Wealth
commercial revenue (-24% YoY). As per our understanding, the company has not made any shipment Stock of its one key product (24% of CMS revenue ) in this calendar year. Reported EBITDA margin contracted by 369bps to 12.8% level (vs our estimate of 15.3%) impacted largely due to Increase in raw material prices and upfront costs for certain projects. However, management is confident of improving margin profile from the current level on the back of a strong order book in CMS business, better traction in GDS business, and cost optimization measures. NLL reported a PAT of INR 87mn...
Number of MF schemes increased from 10 to 16 in Dec 2024 qtr.
More from Neuland Laboratories Ltd.
Recommended